Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer

Romàn Pérez-Soler

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences